VKTXViking Therapeutics, Inc. Common Stock
Chart data are delayed by 15 minutes.
Main metrics
Providers
All 1 issuers →
Dinari Inc.VKTX.d—0.0%Chains
All 5 chains →
Arbitrum One—0.0%
Avalanche C-Chain—0.0%
Base—0.0%
Ethereum—0.0%
Plume—0.0%About VKTX
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for metabolic and endocrine disorders. Viking Therapeutics is advancing a pipeline that includes VK2735, a dual GLP-1/GIP receptor agonist being studied in oral and injectable forms for obesity and other metabolic conditions, along with VK2809, a thyroid hormone receptor beta agonist being evaluated for metabolic liver disease. The company also works on VK0214 for X-linked adrenoleukodystrophy, VK5211 for recovery after hip fracture surgery, VK0612 for metabolic disorders and anemia, and VK3019, an amylin receptor agonist in early study. Based in San Diego, California, Viking Therapeutics is positioned as a research-focused drug developer addressing high-need areas across obesity, liver disease, rare disease, and other endocrine-related conditions.
Valuation
Profitability
Balance sheet
Trading
| Issuer | Token | Chains | Dividend | Shares | Value | Share |
|---|---|---|---|---|---|---|
| Dinari Inc. | VKTX.dViking Therapeutics, Inc. Common Stock (Dinari) | | 0 | — | 0.0% |
| Chain | Issuers | Shares | Value | Share |
|---|---|---|---|---|
| Arbitrum One | | 0 | — | 0.0% |
| Avalanche C-Chain | | 0 | — | 0.0% |
| Base | | 0 | — | 0.0% |
| Ethereum | | 0 | — | 0.0% |
| Plume | | 0 | — | 0.0% |
No dividend has been recorded for this asset.
No corporate event has been recorded for this asset.
